Keros Therapeutics (KROS) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vogenx is the larger company by market cap ($259.6 million vs $241.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | VOGX |
|---|---|---|
| Share price | $12.17 | $17.48 |
| Market cap | $241.30M | $259.59M |
| 1-day change | +4.55% | -0.09% |
| YTD return | -42.83% | — |
| 1-year return | -27.07% | — |
| 5-year return | -70.15% | — |
| EPS (TTM) | $-3.22 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $38.41 |
| 52-week low | $9.69 | $12.95 |
| Distance from 52-week high | -46.03% | -54.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +62.94% | +214.74% |
| Average volume | 194.05K | 187.66K |
| Shares outstanding | 19.83M | 14.86M |
| Employees | 92 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
KROS vs VOGX FAQ
Which is bigger, Keros Therapeutics or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.59M compared with $241.30M for Keros Therapeutics (KROS).
Are Keros Therapeutics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.